

PHARMACOKINETICS

Drug disposition before and after gastric bypass: fenofibrate and posaconazole

Correspondence Professor Patrick Augustijns, PharmD-PhD, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, O&N2, Herestraat 49, Box 921, 3000 Leuven, Belgium. Tel.: + 32 1633 0301; Fax: + 32 1633 0305; E-mail: patrick.augustijns@pharm.kuleuven.be

Received 15 March 2016; **revised** 24 May 2016; **accepted** 22 June 2016

Ina Gesquiere^{1,2}, Bart Hens¹, Bart Van der Schueren², Raf Mols¹, Jan de Hoon³, Matthias Lannoo^{2,4}, Christophe Matthys², Veerle Foulon¹ and Patrick Augustijns¹

¹Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, ²Clinical and Experimental Endocrinology, KU Leuven and Department of Endocrinology, University Hospitals Leuven/KU Leuven, Leuven, Belgium, ³Center for Clinical Pharmacology, University Hospitals Leuven/KU Leuven, Leuven, Belgium, and ⁴Department of Abdominal Surgery, KU Leuven/University Hospitals Leuven, Leuven, Belgium

Keywords absorption, bariatric surgery, fenofibrate, pharmacokinetics, posaconazole, Roux-en-Y gastric bypass

AIMS

Roux-en-Y gastric bypass (RYGB) alters the anatomical structure of the gastrointestinal tract, which can result in alterations in drug disposition. The aim of the present study was to evaluate the oral disposition of two compounds belonging to the Biopharmaceutical Classification System Class II – fenofibrate (bile salt-dependent solubility) and posaconazole (gastric pH-dependent dissolution) – before and after RYGB in the same individuals.

METHODS

A single-dose pharmacokinetic study with two model compounds – namely, 67 mg fenofibrate (Lipanthyl®) and 400 mg posaconazole (Noxafil®) – was performed in 12 volunteers pre- and post-RYGB. After oral administration, blood samples were collected at different time points up to 48 h after administration. Plasma concentrations were determined by high-performance liquid chromatography in order to calculate the area under the concentration–time curve up to 48 h ($AUC_{0-48\text{ h}}$), the peak plasma concentration (C_{max}) and the time to reach peak concentration (T_{max}).

RESULTS

After administration of fenofibrate, no relevant differences in $AUC_{0-48\text{ h}}$, C_{max} and T_{max} between the pre- and postoperative setting were observed. The geometric mean of the ratio of $AUC_{0-48\text{ h}}$ post/pre-RYGB for fenofibrate was 1.10 [95% confidence interval (CI) 0.87, 1.40; $P = 0.40$]. For posaconazole, an important decrease in $AUC_{0-48\text{ h}}$ and C_{max} following RYGB was shown; the geometric mean of the $AUC_{0-48\text{ h}}$ post/pre-RYGB ratio was 0.68 (95% CI 0.48, 0.96; $P = 0.03$) and the geometric mean of the C_{max} pre/post-RYGB ratio was 0.60 (95% CI 0.39, 0.94; $P = 0.03$). The decreased exposure of posaconazole could be explained by the increased gastric pH and accelerated gastric emptying of fluids post-RYGB. No difference for T_{max} was observed.

CONCLUSIONS

The disposition of fenofibrate was not altered after RYGB, whereas the oral disposition of posaconazole was significantly decreased following RYGB.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

- Roux-en-Y gastric bypass (RYGB) has an effect on various factors influencing drug absorption, including an increased gastric pH, delayed inlet of bile acids and reduced surface area.
- Only a few studies have investigated changes in drug disposition after RYGB.

WHAT THIS STUDY ADDS

- The oral disposition of fenofibrate was not altered after RYGB.
- The oral disposition of posaconazole was significantly decreased following RYGB.
- Caution is needed when prescribing basic drugs, which are highly dependent on the acidic environment in the stomach for their solubility/dissolution behaviour.

Introduction

Over recent decades, the prevalence of obesity has increased dramatically. Obesity is associated with several physiological changes which alter drug disposition. The increased prevalence of obesity has led to an increased demand for bariatric surgery, especially Roux-en-Y gastric bypass (RYGB), which offers the most significant and sustainable weight reduction in morbidly obese patients [body mass index (BMI) $\geq 40 \text{ kg m}^{-2}$ or $\geq 35 \text{ kg m}^{-2}$ with obesity-related diseases] based on currently available data [1, 2]. Besides weight loss and subsequently reduced BMI and percentage body fat, RYGB results in anatomical and physiological changes in the gastrointestinal (GI) tract by reducing the gastric capacity and bypassing the duodenum and proximal jejunum [3, 4]. These changes may alter the pharmacokinetics of any given drug. However, the extent to which the absorption of a specific drug or class of drugs is altered remains unknown. The available data show no clear prediction of changes in oral drug exposure before and after RYGB. Oral exposure can be reduced following RYGB (as reported for azithromycin [5]); it can remain unaltered (as reported for levothyroxine [6]); or can be increased (as reported for metformin [7]). A systematic approach to studying the influence of RYGB on oral drug exposure is lacking because of variations in study design and a lack of standardization of surgical procedures, making the results difficult to compare [8]. We have previously performed a pharmacokinetic study of metoprolol in patients pre- and post-RYGB, and the same design was used in the current pharmacokinetic study, allowing direct comparison of the results [9].

As mentioned above, several anatomical and physiological changes are associated with a RYGB. In patients with RYGB, the gastric remnant and bypassed biliary limb are reconnected to the intestine, 75–150 cm distal to the anastomosis between the gastric pouch and the distal part of the jejunum [10]. This alteration in GI anatomy results in a delayed action of bile acids, as bile salts and the drug/food do not come into contact until they reach the common channel in the mid-jejunum. Furthermore, RYGB leads to the formation of a small gastric pouch; this, in addition to the widespread use of antacid medication following surgery, results in an increased gastric pH. The increased gastric pH affects drug dissolution and the solubility of ionizable compounds, and subsequently their absorption [11, 12]. With these changes in mind, we chose our study drugs on the basis of their absorption

characteristics. In the present study, we investigated the influence of RYGB on the disposition of fenofibrate and posaconazole. Both compounds belong to the Biopharmaceutical Classification System (BCS) class II (high permeability, low solubility) [13]. Fenofibrate (neutral) was selected as a test compound because it has been demonstrated that its solubility is highly dependent on bile salt concentrations [14]. In light of a delayed contact with bile salts after surgery, a decrease in absorption was expected. Fenofibrate is a lipid-lowering agent and is available as a micronized formulation (Lipanthy® capsule) and a nanonized formulation (Lipanthylnano® tablet). In the present study, we chose the micronized tablet, as our focus was to analyse the drug substance and not the formulation characteristics. Posaconazole (a weak base) was selected as a model compound in view of the fact that a relationship has been demonstrated between residence time in the acidic environment of the stomach and systemic exposure. As a result of a reduction in acid production and a shorter residence time in the stomach after RYGB, a lower systemic exposure was expected.

Posaconazole is a broad-spectrum anti-fungal drug for the treatment of invasive fungal infections. In the present study, we used the suspension (Noxafil®) [15].

Subjects and methods

Selection of patients

Obese patients with a planned RYGB surgery at the University Hospitals Leuven, Belgium, were recruited. Patients who had previously undergone bariatric surgery or who had renal and hepatic impairment were not included in the study. Pregnant and breastfeeding women were also not included. RYGB surgery was performed in all recruited patients by the same surgeon and according to the same procedure. In brief, the jejunum was divided 30 cm from the ligament of Treitz and anastomosed to a 30 ml proximal gastric pouch. The jejunum was reanastomosed 120 cm distally to the gastrojejunostomy. All mesenteric defects were closed. The study was approved by the medical ethics committee of the University Hospitals Leuven (ML8433) and was performed in accordance with the 1964 Helsinki Declaration and its later amendments. The study is listed in the European Clinical Trials database

(EudraCT), with reference number 2012-001 244-22. All patients gave written informed consent.

Study design and procedure

In one group (12 patients; 11 Caucasian and one of African descent), a single-dose pharmacokinetic study with 67 mg fenofibrate (Lipanthyl®) was performed before and 6–9 months after RYGB [average 6.9 [standard deviation (SD) 1.0] months; further referred to as 6 months after RYGB]. In another group of 12 patients (10 Caucasian, and one of African and one of South American descent), a single-dose pharmacokinetic study with 400 mg posaconazole (10 ml Noxafil®, an oral suspension containing 40 mg ml⁻¹) was performed before and 6–9 months after RYGB [average 6.7 (SD 0.7) months; further referred to as 6 months after RYGB]. As lung cancer was diagnosed in a patient post-RYGB, there was dropout of one participant in the posaconazole study. One of the patients in the posaconazole study had previously undergone a cholecystectomy.

The extent of absorption, distribution, metabolism, and excretion of disposition of fenofibrate and posaconazole was estimated by determining the area under the curve (AUC_{0–48 h}), peak plasma concentration (C_{max}) and time to reach peak concentration (T_{max}) of fenofibric acid and posaconazole, respectively.

Following an overnight fast of at least 10 h, subjects came to the clinical pharmacology unit of the University Hospitals Leuven. Weight and height were measured using calibrated equipment. Weight was measured to the nearest 0.1 kg, with the subjects having an empty bladder and wearing indoor clothing with empty pockets and without shoes. The BMI (kg m⁻²) was calculated by dividing the weight (kg) by the square of the height (m²). The percentage weight loss from baseline was calculated to express the change in weight.

Dual-energy X-ray absorptiometry was performed (Hologic Discovery) to measure the amount of body fat mass [16].

After the insertion of an intravenous catheter, one group of subjects ingested 67 mg fenofibrate with 150 ml water, and the other group ingested 10 ml posaconazole 40 mg ml⁻¹ with 150 ml water. After oral administration, blood samples were collected into heparinized tubes at 15 min, 30 min, 60 min, 90 min, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 24 h and 48 h. The blood samples were centrifuged immediately after collection (1800 g, 10 min, 4°C); plasma samples were stored at –20°C until analysis.

A standardized meal and standardized snack were administered 4 h and 8 h after drug administration, respectively. Participants had to consume the entire meal. The use of water was allowed *ad libitum*, except for 1 h before and 4 h after drug administration. During the first 4 h after administration of the drugs, the patients had to remain semi-supine in bed. After the 10-h blood sample, the subjects were discharged and had to return on the two subsequent mornings for the 24- and 48-h blood sampling. As proton pump inhibitors (PPIs), H₂-receptor antagonists and antacids can influence drug absorption, the recruited patients were asked to stop taking these drugs during the week preceding the study. Other prescription drugs were checked to verify that they had no pharmacokinetic interactions with the study drug. On the

first morning of the study, the patients were not allowed to take any of their medication.

High-performance liquid chromatography (HPLC) analysis

Fenofibrate. After absorption of fenofibrate, it is quantitatively converted to its active metabolite, fenofibric acid [17]. Fenofibric acid was determined in plasma to be indicative of the oral exposure from fenofibrate. Before HPLC-ultraviolet (UV) analysis, fenofibric acid was extracted from plasma samples. 100 µl of a stock solution of the internal standard carbamazepine solution (20 µM in 1 M HCl) was added to 500 µl plasma. Subsequently, 400 µl HCl (1 M) was added and vortexed (±10 s) in order to precipitate plasma proteins. To extract fenofibric acid and carbamazepine, 6 ml dichloromethane was added and samples were shaken for 1 min. After centrifugation (2880 g, 15 min, 4°C), the water layer was discarded and the organic layer was evaporated under a stream of air until dryness. The residue was dissolved in 1 ml methanol. Following evaporation, 200 µl of mobile phase was added to the residue and injected into the HPLC system (Waters, Milford, MA, USA). Carbamazepine and fenofibric acid were detected at a wavelength of 287 nm (Waters 2487 UV Detector). Retention times of 4.5 min and 8 min were generated with a flow rate of 1 ml min⁻¹ for carbamazepine and fenofibric acid, respectively. Running conditions started with acetonitrile: 25 mM acetic acid buffer pH 3.5 (50:50 v/v). Acetonitrile concentrations increased up to 60% over 3 min. Following elution of fenofibric acid, the column was rinsed for 2 min with acetonitrile:water (90:10 v/v), followed by 1 min with water: 25 mM acetic acid buffer pH 3.5 (75:25 v/v) and subsequently re-equilibrated under the starting conditions for 2 min.

The calibration curve was based on a stock solution of fenofibric acid in acetonitrile. Blank plasma samples were spiked and treated the same way as the samples. Linearity was observed between 158 µM and 0.31 µM. Method validation resulted in accuracy and precision errors of less than 5% and 8%, respectively, for a concentration of 9.8 µM. Quality control samples (9.8 µM) were included on the days of analysis and resulted in a relative SD of less than 5%.

Posaconazole. Analysis was performed by extracting posaconazole from plasma samples as described by Walravens *et al.* [27]. Concentrations of posaconazole were determined using HPLC/fluorescence analysis. Briefly, 100 µl of internal standard solution (2.5 µM itraconazole in 0.2 N HCl) was added to 1000 µl of plasma. Subsequently, the sample was alkalinized with 500 µl 2 N NaOH. After addition of 4 ml diethylether, samples were vortexed for 30 s and directly centrifuged (2880 g, 5 min, 4°C). Finally, the organic layer was transferred to a clean glass tube and evaporated to dryness under a gentle stream of air. A volume of 300 µl of the mobile phase [methanol:20 mM acetic acid buffer pH 3.3 (76:24 v/v)] was added to the remaining residue. After centrifugation (2880 g, 5 min, 4°C), 50 µl of the supernatant was injected into the Hitachi Elite LaChrom HPLC system and analysed by the Hitachi Elite LaChrom L-2480 fluorescence detector (excitation wavelength 240 nm,

emission wavelength 385 nm). A gradient run of 19 min was performed in order to obtain a retention time of 7.9 min and 12.1 min on the Novapak C-18 column for posaconazole and itraconazole, respectively. Gradient elution at a constant flow rate of 1 ml min⁻¹ was performed as follows: methanol:20 mM acetic acid buffer pH 3.3 (76:24) for 2 min followed by methanol:20 mM acetic acid buffer pH 3.3 (81:19) for 7 min; followed by a rinsing step with 100% methanol for 3 min; then re-equilibration for 5 min with methanol:20 mM acetic acid buffer pH 3.3 (76:24) before the next injection. A calibration curve was made based on stock solutions of posaconazole and itraconazole in dimethyl sulfoxide. Linearity was observed between 2000 nM and 7.8 nM. Quality control samples of 500 nM and 50 nM, which were analysed together with the plasma samples, resulted in an accuracy and precision error of less than 10%.

Data analysis

The AUC_{0-48 h} of the concentration–time curves was determined using the linear trapezoidal rule. All results are presented as mean (95% CI). To compare the characteristics of the patients, paired *t*-tests were performed. To estimate the magnitude of the effect of RYGB on the disposition of fenofibrate/posaconazole, a ratio paired *t*-test was performed, determining the geometric mean of the ratios (post/pre) with 95% CI for AUC_{0-48 h} and C_{max}, or the mean difference (pre-post) with 95% CI for T_{max}. For that purpose, the values of AUC_{0-48 h} and C_{max} were log-transformed, the difference between the transformed variables was estimated with 95% CI, and the mean and confidence limits were back-transformed to the original scale. The preoperative data for the patient who dropped out of the posaconazole study were omitted from the analysis. Data were analysed using SPSS Statistics 22 (IBM Corp., Armonk, New York, USA). Multiple linear

regression analysis was performed to investigate if there was a correlation between the difference in AUC_{0-48 h} and gender, age, difference in BMI, fat percentage and percentage weight loss. Statistical significance was set at *P* < 0.05.

Results

Fenofibrate

For the fenofibrate study, 12 patients (seven female) with a mean age of 43.3 (95% CI 34.0, 52.6) years were included and completed follow-up. Weight, BMI, percentage weight loss, and total and abdominal fat mass percentage were significantly decreased post-RYGB (see Table 1).

The observed concentration–time profiles are shown in Figure 1. The mean AUC_{0-48 h}, AUC from 0 to infinity (AUC_{0-∞}) and C_{max} were comparable before and after RYGB, as shown in Table 2. The geometric mean of the ratio of AUC_{0-48 h} post/pre-RYGB for fenofibrate was 1.10 (95% CI 0.87, 1.40; *P* = 0.40) and the geometric mean of the ratio of C_{max} post/pre-RYGB was 1.12 (95% CI 0.79, 1.59; *P* = 0.49). The mean difference in T_{max} was -0.58 h (95% CI -4.72, 3.55).

When comparing the individual AUC_{0-48 h} postoperatively with preoperatively, two patients had a >25% decrease in AUC_{0-48 h} and four had a >25% increase in AUC_{0-48 h}. For the others, the AUC_{0-48 h} was comparable before and after surgery. No correlation with other variables was identified.

Posaconazole

For the posaconazole study, 12 patients were included, 11 of whom (seven female), with a mean age of 37.4 (95% CI 30.0, 44.7) years, completed the study. Weight, BMI,

Table 1

Characteristics of the participants, shown as mean [95% confidence interval (CI)]

	Before RYGB	After RYGB	<i>P</i> value
Fenofibrate (n = 12)			
Weight (kg)	118 (105, 131)	83.7 (74.2, 93.2)	<0.001
BMI (kg m⁻²)	40.4 (38.2, 42.6)	28.8 (26.6, 30.9)	<0.001
Percentage weight loss	-	28.8 (25.7, 31.8)	<0.001
Total fat percentage	42.5 (38.2, 46.8)	31.0 (25.0, 37.0)	<0.001
Abdominal fat percentage	44.0 (41.2, 46.7)	29.1 (23.8, 34.4)	<0.001
Posaconazole (n = 11)			
Weight (kg)	123 (110, 135)	87.2 (77.7, 96.7)	<0.001
BMI (kg m⁻²)	40.8 (37.0, 44.6)	29.0 (26.2, 31.8)	<0.001
Percentage weight loss	-	28.8 (24.4, 33.3)	<0.001
Total fat percentage	41.9 (36.8, 47.0)	31.6 (25.9, 37.4)	<0.001
Abdominal fat percentage	41.9 (36.8, 47.1)	28.3 (23.0, 33.5)	<0.001

BMI, body mass index; RYGB, Roux-en-Y gastric bypass.




Figure 1

Observed plasma concentration–time profiles of fenofibrate over 48 h after oral administration, shown as mean concentration \pm standard error of the mean. \blacklozenge Preoperative, \blacksquare Postoperative




Figure 2

Observed plasma concentration–time profiles of posaconazole over 48 h after oral administration, shown as mean concentration \pm standard error of the mean. \blacklozenge Preoperative, \blacksquare Postoperative

Table 2

Pharmacokinetic parameters, shown as mean [95% confidence interval (CI)]

	Before RYGB	After RYGB
Fenofibrate (n = 12)		
AUC_{0–48 h} ($\mu\text{g ml}^{-1} \cdot \text{h}$)	31.3 (21.8, 40.8)	33.3 (25.0, 41.5)
AUC_{0–∞} ($\mu\text{g ml}^{-1} \cdot \text{h}$)	46.9 (29.6, 64.2)	51.7 (32.4, 71.1)
C_{max} ($\mu\text{g ml}^{-1}$)	1.37 (0.87, 1.87)	1.57 (1.01, 2.12)
T_{max} (h)	4.54 (3.38, 5.70)	5.12 (1.23, 9.02)
Posaconazole (n = 11)		
AUC_{0–48 h} ($\mu\text{g ml}^{-1} \cdot \text{h}$)	3.11 (1.38, 4.85)	1.81 (1.37, 2.26)
AUC_{0–∞} ($\mu\text{g ml}^{-1} \cdot \text{h}$)	9.49 (5.26, 13.7)	4.37 (2.91, 5.84)
C_{max} ($\mu\text{g ml}^{-1}$)	0.12 (0.04, 0.21)	0.06 (0.04, 0.07)
T_{max} (h)	7.68 (–1.52, 16.9)	6.46 (2.43, 10.5)

AUC_{0–48 h}, area under the concentration–time curve up to 48 h; AUC_{0–∞}, area under the concentration–time curve from 0 to infinity; C_{max}, peak plasma concentration; RYGB, Roux-en-Y gastric bypass; T_{max}, time to reach peak concentration.

percentage weight loss, and total and abdominal fat mass percentage were significantly decreased post-RYGB (see Table 1).

The observed concentration–time profiles are shown in Figure 2. The RYGB had an important impact on the AUC_{0–48 h} and AUC_{0–∞} after oral administration of posaconazole, as shown in Table 2. The geometric mean of the ratio of AUC_{0–48 h} post/pre-RYGB was 0.68 (95% CI 0.48, 0.96; $P = 0.03$). C_{max} was also decreased after surgery; the geometric mean of the ratio for C_{max} post/pre-RYGB was 0.60 (95% CI 0.39, 0.94; $P = 0.03$). The difference in T_{max} was 1.23 h (95% CI –8.86, 11.31). No correlation with other variables was identified.

Discussion

We investigated the pharmacokinetic parameters of a neutral compound (fenofibrate) and a weak base (posaconazole) in patients before and after RYGB. We showed that the mean pharmacokinetic parameters of the neutral compound (fenofibrate) were unaltered after RYGB, whereas for the weak base (posaconazole), the oral exposure was decreased after RYGB.

Both fenofibrate and posaconazole are lipophilic drugs belonging to BCS class II (low solubility, high permeability). The solubility of fenofibrate is highly dependent on bile acid/phospholipid concentrations [14]. These ingredients are responsible for the formation of micelles, which increase the solubility of lipophilic drugs. RYGB changes the anatomical structure of the GI tract, resulting in a delayed inlet of bile acids [10]. This could explain the delayed exposure of fenofibrate to bile acids, which can result in a reduced exposure after oral administration. However, the mean oral exposure of fenofibrate was comparable before and after RYGB. This could be explained by a compensation mechanism after RYGB. Patti *et al.* [19] showed that the fasting total serum bile acid concentration is twice as high in patients 2–4 years after RYGB, compared with overweight or obese individuals without bariatric surgery. This was confirmed in patients 4 days and 1 year post-RYGB [20]. This increase might be associated with an increased secretion of bile acids in the small intestine, compensating for the delayed inlet of bile acids post-RYGB and resulting in no relevant impact of RYGB on the pharmacokinetic parameters of oral fenofibrate disposition after this intervention. However, no information about the intestinal concentration of bile acids post-RYGB is available. Interestingly, no increase in T_{max} was observed for fenofibrate. It is possible to hypothesize that the interval between administration of the drug and its subsequent contact with bile acids is comparable before and after surgery, despite the delayed inlet of bile acids. An explanation could be that the delayed inlet of bile acids might be compensated by the accelerated gastric

emptying of fluids after RYGB and thus be similar; accelerated gastric emptying has already been demonstrated in previous studies [21–25]. Furthermore, the changes in body composition can influence fenofibrate disposition, although no information about the impact of obesity on fenofibrate disposition is available. It is worth mentioning that large interindividual differences were observed: some patients had a decrease in the oral exposure of fenofibrate, and others an increase; for most patients, the oral exposure pre- and postoperatively was the same. This might reflect large inter- and intraindividual differences in the amount of bile acid secretion, which have also been shown in healthy volunteers [26].

Posaconazole is a lipophilic, weak base and we have demonstrated an important decrease in $AUC_{0-48\text{ h}}$ and C_{max} post-RYGB. Dissolved posaconazole might be absorbed quickly as it has a high permeability [27]. However, it has a low solubility, and the intraluminal pH and the residence time in the stomach have an important role in the intestinal absorption of this agent; a previous study showed that an increase in gastric pH is associated with a reduction in the absorption of posaconazole, while a longer residence time in the stomach increased absorption [18]. These findings were confirmed by Krishna *et al.*, who showed that the oral exposure and C_{max} of posaconazole were decreased if the gastric pH was increased by the intake of a PPI (esomeprazole), and were increased when posaconazole was administered with an acidic beverage [28]. In patients undergoing RYGB, a small gastric pouch is created, in which gastric acid secretion is negligible as the majority of the parietal cells (i.e. acid-producing cells) are bypassed [11, 12]. This results in an elevated gastric pH, which affects the solubility of drugs, including posaconazole as a weak base. In the present study, the mean $AUC_{0-48\text{ h}}$ and C_{max} were decreased after RYGB by 42% and 50%, respectively, compared with 37% and 42%, respectively, in patients using esomeprazole [18]. This suggests that the increase in gastric pH is not the only contributor to the reduction in oral exposure postoperatively. After RYGB, the residence time in the stomach is also changed. It has also been shown that gastric emptying for liquids is accelerated after RYGB [21–25]. Faster gastric emptying is associated with a shorter gastric residence time, and subsequently a shorter dissolving period for posaconazole, eventually resulting in a reduced $AUC_{0-48\text{ h}}$ and C_{max} , and especially a reduction in the rate and extent of absorption. Furthermore, the reduction in body weight post-RYGB can have an impact on the disposition of posaconazole. However, posaconazole dosages should not be changed for increased body weight, although follow-up studies are needed to investigate the impact of obesity on the disposition of posaconazole [29].

These observations may have significant clinical implications. The results from the present study might explain why posaconazole was found to be ineffective in a patient who had undergone RYGB [30]. The patient was treated with posaconazole for 10 days and the levels were well below the minimal inhibitory concentration, despite strict adherence and no coadministration of a medication that could interfere with the absorption of posaconazole. A switch to oral isavuconazole was necessary in this case [30]. Isavuconazole is a BCS class I compound (high solubility and high permeability) [31]; this might explain why its disposition is less influenced by RYGB, as in a previous pharmacokinetic study of

metoprolol, another BCS class I compound, we showed that RYGB had no significant impact on its oral exposure [9]. However, it should be noted that the results for isavuconazole were from a case report and we do not know the generalizability of this finding. This case report highlights the importance of pharmacokinetic studies in the RYGB patient population in order to avoid underdosing. Therapeutic drug monitoring for posaconazole after RYGB should be considered in order to ensure that minimal inhibitory concentrations are reached.

Furthermore, we need to take into account that obesity is associated with many changes in body composition, which can have an influence on the volume of distribution (V_D), especially for lipophilic compounds. In general, lipophilic compounds will have an increase in V_D in obese vs. normal-weight individuals, although there are exceptions [31, 32]. Both fenofibrate and posaconazole are lipophilic drugs and may be associated with an increase in V_D before RYGB as obesity is associated with an excessive fat mass accumulation. Posaconazole, in particular, has a remarkable distribution in the body; one study found a 40-fold higher concentration in the tissue than in the serum [33]. We have shown that the fat mass percentage after surgery was significantly decreased, which might have resulted in a decreased V_D post-RYGB. These changes might be reflected in lower plasma concentrations before surgery.

To increase the solubility of posaconazole, coadministration of an acidic carbonated beverage, such as Coca-Cola®, can help [18]. However, in patients who have undergone RYGB, the intake of such drinks is not recommended as it can result in gastric problems and dumping syndrome [34]. Furthermore, the intake of fenofibrate and posaconazole with high-fat food could increase intraluminal solubility by increasing bile acid flow [33]. However, in the present study we preferred to administer the drugs in a fasted state, for two reasons. First, the results on the gastric emptying of solids after RYGB are contradictory [23, 25]. This implies that if the drug was administered during a fed state, more interindividual differences would be observed. Furthermore, we wanted to use the same design as in our previously performed pharmacokinetic study of metoprolol, in order to enable a comparison to be made between the different drugs analysed [9].

Recently, a delayed-release tablet formulation containing 100 mg posaconazole was developed using the hot-melt extrusion technique, in which posaconazole is dispersed in hypromellose acetate succinate, which is pH sensitive [33]. The tablet has the advantage that it results in a higher exposure to the drug, and this may be accompanied by fewer interindividual differences. Moreover, this exposure is not affected by changes in motility or gastric pH [33]. It is possible that the increased gastric pH post-RYGB has less influence on posaconazole exposure from the tablet formulation than from the oral suspension. In a future study, it would be interesting to test the tablet formulation of posaconazole in this population group, in order to have a better idea of the influence of RYGB on different formulations of the same drug, as we have already done for metoprolol (immediate- and controlled-release formulation). Based on the results of the pharmacokinetic studies performed with metoprolol, fenofibrate and posaconazole in patients before and after RYGB, we can state that caution is especially needed when

prescribing basic drugs which are highly dependent on the acidic environment in the stomach for dissolution/solubility. Overall, the strength of the present pharmacokinetic study was the design as it was performed in the same patient group both before and after the operation, ensuring that there were no interindividual differences between the groups. Furthermore, the patients underwent the same type of surgery, performed by the same surgeon.

In conclusion, fenofibrate and posaconazole are both BCS class II compounds with high permeability and low solubility, but fenofibrate is a neutral compound and posaconazole a weak base. The pharmacokinetic parameters for the disposition of fenofibrate were found to be comparable before and after RYGB. This was in contrast with the important decrease in the oral exposure of posaconazole after RYGB, which could be explained by the increase in gastric pH and accelerated gastric emptying of fluids post-RYGB. Caution is needed when prescribing other basic drugs which are highly dependent on the acidic environment in the stomach for dissolution/solubility. The disposition of these drugs might also be decreased, resulting in underdosing.

Competing Interests

All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

We would like to thank all study participants. IG received a PhD scholarship from the Agency for Innovation by Science and Technology, Flanders, IWT-111 328. BVdS is the recipient of a 'Fundamenteel Klinisch Navorserschap FWO Vlaanderen'.

Contributors

IG, BH, BVDS, RM, JdH, ML, CM, VF and PA wrote the manuscript. IG, BVDS, JdH, ML, CM, VF and PA designed the research. IG, BH and RM performed the research. IG, BH, BVDS, CM, VF and PA analysed the data.

References

- 1 WHO – Obesity and overweight 2015. Fact sheet N°311.
- 2 Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, *et al.* The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. *Health Technol Assess* 2009; 13: 215–357.
- 3 De Smet J, Van Boxlaer J, Boussery K. The influence of bypass procedures and other anatomical changes in the gastrointestinal tract on the oral bioavailability of drugs. *J Clin Pharmacol* 2013; 53: 361–76.
- 4 Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. *Obes Rev* 2010; 11: 41–50.
- 5 Padwal RS, Ben-Eltriki M, Wang X, Langkaas LA, Sharma AM, Birch DW, *et al.* Effect of gastric bypass surgery on azithromycin oral bioavailability. *J Antimicrob Chemother* 2012; 67: 2203–6.
- 6 Gkotsina M, Michalaki M, Mamali I, Markantes G, Sakellaropoulos GC, Kalfarentzos F, *et al.* Improved levothyroxine pharmacokinetics after bariatric surgery. *Thyroid* 2013; 23: 414–9.
- 7 Padwal RS, Gabr RQ, Sharma AM, Langkaas LA, Birch DW, Karmali S, *et al.* Effect of gastric bypass surgery on the absorption and bioavailability of metformin. *Diabetes Care* 2011; 34: 1295–300.
- 8 Greenblatt HK, Greenblatt DJ. Altered drug disposition following bariatric surgery: a research challenge. *Clin Pharmacokinet* 2015; 54: 573–9.
- 9 Gesquiere I, Darwich AS, Van der Schueren B, de Hoon J, Lannoo M, Matthys C, *et al.* Drug disposition and modelling before and after gastric bypass: immediate and controlled release metoprolol formulations. *Br J Clin Pharmacol* 2015; 80: 1021–30.
- 10 Neff KJ, Olbers T, le Roux CW. Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes. *BMC Med* 2013; 11: 8.
- 11 Smith CD, Herkes SB, Behrns KE, Fairbanks VF, Kelly KA, Sarr MG. Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity. *Ann Surg* 1993; 218: 91–6.
- 12 Behrns KE, Smith CD, Sarr MG. Prospective evaluation of gastric acid secretion and cobalamin absorption following gastric bypass for clinically severe obesity. *Dig Dis Sci* 1994; 39: 315–20.
- 13 Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. *Pharm Res* 2005; 22: 11–23.
- 14 Mohsin K. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion. *AAPS PharmSciTech* 2012; 13: 637–46.
- 15 Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. *Clin Ther* 2007; 29: 1862–86.
- 16 Bazzocchi A, Ponti F, Cariani S, Diano D, Leuratti L, Albisinni U, *et al.* Visceral fat and body composition changes in a female population after RYGBP: a two-year follow-up by DXA. *Obes Surg* 2015; 25: 443–51.
- 17 Guivarc'h PH, Vachon MG, Fordyce D. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. *Clin Ther* 2004; 26: 1456–69.
- 18 Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. *Clin Pharmacokinet* 2011; 50: 725–34.
- 19 Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, *et al.* Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. *Obesity (Silver Spring)* 2009; 17: 1671–7.
- 20 Simonen M, Dali-Youcef N, Kaminska D, Venesmaa S, Käkälä P, Pääkkönen M, *et al.* Conjugated bile acids associate with altered

- rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. *Obes Surg* 2012; 22: 1473–80.
- 21** Wang G, Agenor K, Pizot J, Kotler DP, Harel Y, Van Der Schueren BJ, *et al.* Accelerated gastric emptying but no carbohydrate malabsorption 1 year after gastric bypass surgery (GBP). *Obes Surg* 2012; 22: 1263–7.
- 22** Naslund I, Beckman KW. Gastric emptying rate after gastric bypass and gastroplasty. *Scand J Gastroenterol* 1987; 22: 193–201.
- 23** Horowitz M, Cook DJ, Collins PJ, Harding PE, Hooper MJ, Walsh JF, *et al.* Measurement of gastric emptying after gastric bypass surgery using radionuclides. *Br J Surg* 1982; 69: 655–7.
- 24** Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, *et al.* Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. *J Clin Endocrinol Metab* 2006; 91: 1735–40.
- 25** Dirksen C, Damgaard M, Bojsen-Moller KN, Jorgensen NB, Kielgast U, Jacobsen SH, *et al.* Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. *Neurogastroenterol Motil* 2013; 25: 346–e255.
- 26** Riethorst D, Mols R, Duchateau G, Tack J, Brouwers J, Augustijns P. Characterization of human duodenal fluids in fasted and fed state conditions. *J Pharm Sci* 2015; 105: 673–81.
- 27** Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, *et al.* Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. *Antimicrob Agents Chemother* 2006; 50: 1993–9.
- 28** Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. *Antimicrob Agents Chemother* 2009; 53: 958–66.
- 29** Payne KD, Hall RG. Dosing of antifungal agents in obese people. *Expert Rev Anti Infect Ther* 2016; 14: 257–67.
- 30** Knoll BM. Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery. *J Antimicrob Chemother* 2014; 69: 3441–3.
- 31** Schmitt-Hoffmann A, Roos B, Maeres J, Heep M, Spickerman J, Weidekamm E, *et al.* Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. *Antimicrob Agents Chemother* 2006; 50: 286–93.
- 32** Martin JH, Saleem M, Looke D. Therapeutic drug monitoring to adjust dosing in morbid obesity – a new use for an old methodology. *Br J Clin Pharmacol* 2012; 73: 685–90.
- 33** Percival KM, Bergman SJ. Update on posaconazole pharmacokinetics: comparison of old and new formulations. *Curr Fungal Infect Rep* 2014; 8: 139–45.
- 34** Tack J, Deloose E. Complications of bariatric surgery: dumping syndrome, reflux and vitamin deficiencies. *Best Pract Res Clin Gastroenterol* 2014; 28: 741–9.